Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

11. Februar 2025 08:30 ET | Quelle: Alkeus Pharmaceuticals

Alkeus Pharmaceuticals Announces Two Presentations of Oral Gildeuretinol Data During the 48th Annual Meeting of the Macula Society Being Held February 12-15, 2025

CAMBRIDGE, Mass., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Alkeus Pharmaceuticals, Inc., a biopharmaceutical company dedicated to preserving the sight of individuals impacted by retinal diseases, today...
28. Januar 2025 07:05 ET | Quelle: Clearside Biomedical, Inc.

Clearside Biomedical Announces Multiple Medical Meeting Presentations Focused on the Advantages of Suprachoroidal Delivery and Key Differentiators in its CLS-AX Clinical Program

- Upcoming Presentations at Angiogenesis and Macula Society Conferences to Feature CLS-AX Sub-Group Analyses from ODYSSEY Wet AMD Trial - - CLS-AX Targets Flexible Dosing of Biologics with Duration...
07. Februar 2023 07:05 ET | Quelle: Clearside Biomedical, Inc.

Clearside Biomedical OASIS Data to be Presented at Multiple Upcoming Medical Meetings in February 2023

ALPHARETTA, Ga, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the...
08. Februar 2021 07:05 ET | Quelle: Clearside Biomedical, Inc.

Clearside Biomedical Featured in Multiple Data Presentations at the 44th Virtual Annual Macula Society Meeting

- Proprietary suprachoroidal injection platform demonstrates broad applicability across multiple retinal disorders - - CLS-AX will also be featured at the upcoming virtual Angiogenesis, Exudation,...